Skip to content

Arvinas ARVN Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)

Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:OtherReceivablesNetCurrent.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)?
Arvinas (ARVN) reported other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) of $4.6M in Q1 2026.
How has Arvinas's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) changed year-over-year?
Arvinas's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) decreased by 42.5% year-over-year, from $8M to $4.6M.
What is the long-term trend for Arvinas's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)?
Over 5 years (2020 to 2025), Arvinas's other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025) has grown at a -6.1% compound annual growth rate (CAGR), from $7.4M to $5.4M.